KALA — KALA BIO, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1479419 ·
Last close
$2.17
Market Cap
$40.34M
52W High
$25.50
52W Low
$2.11
ADV30
82,864
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,802,000 | -1,621,000 | 12,318,000 | 1,764,000 | 1,557,000 |
| Dec 2025 | 0 | — | -10,225,000 | 686,000 | 9,490,000 | 7,557,000 | 2,494,000 |
| Sep 2025 | 0 | — | -10,181,000 | -7,564,000 | 25,021,000 | 21,096,000 | 33,686,000 |
| Jun 2025 | 0 | — | -10,328,000 | -11,155,000 | 36,053,000 | 31,942,000 | 39,259,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-31,991,000
Investing CF
$-15,000
Financing CF
$-11,618,000
CapEx
$-159,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.93
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-694,900,000
Inventory
—
Receivables
$8,000
ST Investments
—
EBIT TTM
$-23,704,000
Pretax Income TTM
$-26,980,000
Interest Exp TTM
$3,276,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -39,032,000 | -26,980,000 | 9,490,000 | 2,494,000 | — | -31,991,000 |
| Dec 2024 | 0 | -34,235,000 | -38,511,000 | 55,483,000 | 43,151,000 | — | -29,382,000 |
| Dec 2023 | 0 | -34,328,000 | -42,199,000 | 55,949,000 | 48,445,000 | — | -27,927,000 |
| Dec 2022 | 3,892,000 | -81,356,000 | -44,822,000 | 86,820,000 | 67,846,000 | — | -78,908,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IXHL | Incannex Healthcare Inc. | $40.20M | $3.36 | — |
| ZYBT | Zhengye Biotechnology Holding Ltd | $40.75M | $0.86 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $40.93M | $0.97 | — |
| RNXT | RenovoRx, Inc. | $41.30M | $0.92 | — |
| TLPH | TALPHERA, INC. | $41.52M | $0.80 | — |
News headlines (Yahoo Finance, 1h cache)
KALA BIO Announces Reverse Stock Split
2026-05-07 13:00 · Yahoo
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
2026-04-28 12:00 · Yahoo
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
2026-04-21 11:00 · Yahoo
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
2026-04-01 10:45 · Yahoo
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
2026-03-30 12:45 · Yahoo
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
2026-03-18 13:00 · Yahoo
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
2026-03-18 12:15 · Yahoo
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents
2026-03-11 15:18 · Yahoo
BC-Most Active Stocks
2026-03-11 14:30 · Yahoo
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
2026-03-11 10:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.